FEV1 · adults with asthma not well controlled on ICS
1 finding from 1 review
ACQ score Scale = 0 to 6 (0 = no impairment; 6 = maximum impairment) · adults with asthma not well controlled on ICS
1 finding from 1 review
Adverse events (all) · adults with asthma not well controlled on ICS
Long‐acting muscarinic antagonists (LAMA) add‐on showed no clear difference in adverse events (all) compared with long‐acting beta2‐agonists (LABA) add‐on (moderate certainty).
1 finding from 1 review
Treatment failure Need to intensify therapy/ED or hospital admission · exacerbations of COPD
Systemic corticosteroid leads to lower treatment failure Need to intensify therapy/ED or hospital admission compared with placebo (high certainty).
1 finding from 1 review
Mortality after discharge (1‐3 months) · exacerbations of COPD
Treatment route: intravenous corticosteroid showed no clear difference in mortality after discharge (1‐3 months) compared with oral corticosteroid (moderate certainty).
1 finding from 1 review
Length of hospitalisation (days) · exacerbations of COPD
1 finding from 1 review
Adverse drug effect—hyperglycaemia · exacerbations of COPD
Treatment route: intravenous corticosteroid probably leads to higher adverse drug effect ‐ hyperglycaemia compared with oral corticosteroid (moderate certainty).
1 finding from 1 review
Arterial blood gas tension: PaO2 after 3 months mmHg · exacerbations of COPD
1 finding from 1 review
Relapse Treatment for AE of COPD or hospital re‐admission · exacerbations of COPD
Systemic corticosteroid showed no clear difference in relapse Treatment for AE of COPD or hospital re‐admission compared with placebo (moderate certainty).
1 finding from 1 review
FEV1 · exacerbations of COPD
1 finding from 1 review
Breathlessness ‐ early effect VAS 0‐10. Scale from: 0 to 10. · exacerbations of COPD
1 finding from 1 review
Adverse drug reactions · exacerbations of COPD
Systemic corticosteroid leads to higher adverse drug effect compared with placebo (high certainty).
1 finding from 1 review
Hyperglycaemia · exacerbations of COPD
Systemic corticosteroid leads to higher hyperglycaemia compared with placebo (high certainty).
1 finding from 1 review
Treatment failure Need for additional treatment · exacerbations of COPD
Treatment route: intravenous corticosteroid showed no clear difference in treatment failure Need to intensify therapy compared with oral corticosteroid (moderate certainty).
1 finding from 1 review
Relapse Hospital readmission for COPD · exacerbations of COPD
Treatment route: intravenous corticosteroid showed no clear difference in relapse Hospital readmission for COPD compared with oral corticosteroid (moderate certainty).
1 finding from 1 review
Breathlessness ‐ early effect VAS 0‐10. Scale from: 0 to 10. · exacerbations of COPD
1 finding from 1 review
Change from baseline in morning PEFR (L/min) Duration of trials: 8 to 13 weeks · patients with chronic asthma
1 finding from 1 review
Lung function: FEV1 mL (change from baseline) · patients with chronic asthma
1 finding from 1 review
Rescue‐free days: % change from baseline · patients with chronic asthma
1 finding from 1 review
Use of rescue medication · patients with chronic asthma
1 finding from 1 review